Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Lxs196
2. Lxs-196
3. 1874276-76-2
4. Nvp-lxs196
5. Nvp-lxs-196
6. Ide196
7. Ide-196
8. Darovasertib [usan]
9. E0yf0m8o09
10. 3-amino-n-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
11. 3-amino-n-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
12. 2-pyrazinecarboxamide, 3-amino-n-(3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl)-6-(3-(trifluoromethyl)-2-pyridinyl)-
13. Darovasertib [inn]
14. Unii-e0yf0m8o09
15. Darovasertib [who-dd]
16. Chembl3982723
17. Schembl17506262
18. Gtpl11186
19. Bdbm251460
20. Bcp20781
21. Ex-a2690
22. Zzc27676
23. Nsc800030
24. S6723
25. Zb1591
26. Zinc584641445
27. Cs-7529
28. Nsc-800030
29. Example 9 [wo2016020864a1]
30. Ac-36337
31. Ws-01966
32. Hy-101569
33. D85524
34. Us9452998, 9
35. Q29213686
| Molecular Weight | 472.5 g/mol |
|---|---|
| Molecular Formula | C22H23F3N8O |
| XLogP3 | 1.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 4 |
| Exact Mass | 472.19469187 g/mol |
| Monoisotopic Mass | 472.19469187 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 702 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Darovasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Darovasertib, including repackagers and relabelers. The FDA regulates Darovasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Darovasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Darovasertib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Darovasertib supplier is an individual or a company that provides Darovasertib active pharmaceutical ingredient (API) or Darovasertib finished formulations upon request. The Darovasertib suppliers may include Darovasertib API manufacturers, exporters, distributors and traders.
click here to find a list of Darovasertib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Darovasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Darovasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Darovasertib GMP manufacturer or Darovasertib GMP API supplier for your needs.
A Darovasertib CoA (Certificate of Analysis) is a formal document that attests to Darovasertib's compliance with Darovasertib specifications and serves as a tool for batch-level quality control.
Darovasertib CoA mostly includes findings from lab analyses of a specific batch. For each Darovasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Darovasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Darovasertib EP), Darovasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Darovasertib USP).
LOOKING FOR A SUPPLIER?
